In summary, serum GP73 is an independent risk factor for significant liver fibrosis in MASLD, and the GFA model based on GP73 combined with LSM has good diagnostic efficacy for significant liver fibrosis, effectively reducing the need for liver biopsy pathology in MASLD patients. The gene discussed is GOLM1; the disease is Hepatic fibrosis.